Argenx presents new efgartigimod data at EULAR 2025
11th June 2025 Uncategorised 0Rheumatology studies show promising results for Sjogren’s disease More: Argenx presents new efgartigimod data at EULAR 2025 Source: News
read more
Rheumatology studies show promising results for Sjogren’s disease More: Argenx presents new efgartigimod data at EULAR 2025 Source: News
read moreAfter combining on the development of five malaria vaccine candidates since 2016, Swedish CDMO Recipharm and the University of Oxford have expanded their collaboration to include additional manufacturing duties. More: Oxford taps CDMO Recipharm to handle additional manufacturing work in
read moreMedical groups, public health leaders and lawmakers were quick to condemn Monday’s announcement that all 17 sitting members of the Advisory Committee on Immunization Practices are being removed. More: 'All innuendo and conspiracy'—RFK Jr.'s vaccine advisory overhaul undermines vaccine confidence,
read moreTravere Therapeutics has turned music mogul, bringing together a singer-songwriter and Grammy-winning producer to create an anthem for the focal segmental glomerulosclerosis community. More: Travere taps Grammy-winning producer to create anthem for kidney disease patients Source: fierce
read moreInsmed hopes to bring treprostinil palmitil inhalation powder, a prodrug of United Therapeutics’ blockbuster PAH mainstay Tyvaso, to phase 3 development by the end of this year. More: Insmed's 'unprecedented' phase 2 PAH win sends stocks soaring as the race
read moreAfter a strong start to the year—as evidenced by the nearly 30% year-over-year increase in the top 10 brands’ first-quarter TV drug ad outlay—spending on pharmaceutical commercials has slowed throughout the second quarter so far. More: TV drug ad spending
read more© 1994 - 2026 B.M. Pharmaceuticals